Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

#17-683 Listing of Mini futures issued by Vontobel Financial Products GmbH

As from July 21, 2017, 92 Mini futures issued by Vontobel Financial Products GmbH will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: Vontobel Financial Products GmbH Type of security: Mini futures, open ended Execution: Automatic cash settlement Term: As from July 21, 2017 and forward or until time for knock out event Market Maker: Bank Vontobel Europe AG Underlying: Euro-Bund Futures - German Government Bond Novo Nordisk Pandora AS Genmab Marine Harvest ASA Subsea 7

#17-682 Listing of Knock out warrants issued by Vontobel Financial Products GmbH

As from July 21, 2017, 15 Knock out warrants issued by Vontobel Financial Products GmbH will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: Vontobel Financial Products GmbH Type of security: Knock out warrants, open ended Execution: Automatic cash settlement Term: As from July 21, 2017 and forward or until time for knock out event Market Maker: Bank Vontobel Europe AG Underlying: Euro-Bund Futures - German Government Bond Boliden AB Hennes & Mauritz AB, H & M ser. B Silver (

Episurf Medical reports brief clinical update

Episurf Medical’s (NASDAQ: EPIS B) first 15 patients have now had their Episealer® implants for more than 3 years. Episurf Medical continues to support the collection of clinical data demonstrating the positive impact Episealer patients experience from the company’s unique, personalised solution for the treatment of knee pain. A significant amount of data has been collected on the growing cohort of Episealer patients, with the first patient still performing very well, nearly 5 years since the treatment. Importantly, the data now shows the clinical relevance and benefits patients experience

#17-681 Listing of Turbo warrant issued by BNP Paribas Issuance B.V.

As from July 21, 2017, 1 Turbo warrant issued by BNP Paribas Issuance B.V. will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instrument will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Call Turbo warrant of European type Execution: Automatic cash settlement Term: As from July 21, 2017 to expiry date Market Maker: BNP Paribas Arbitrage SNC Underlying: DAX 30 Index For more details see attached file. For further information concerning this NDX notice please contact: NDX Listing on +46 8 566

#17-680 Listing of Mini future issued by BNP Paribas Issuance B.V.

As from July 21, 2017, 1 Mini future issued by BNP Paribas Issuance B.V. will be listed on NDX Sweden and will be included on the list for Knock-Outs. The instrument will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Mini future, open ended Execution: Automatic cash settlement Term: As from July 21, 2017 and forward or until time for knock out event Market Maker: BNP Paribas Arbitrage SNC Underlying: ICE Brent Crude Oil Futures Current values of strike and barrier can be found at: [ NGM Market Data Web - MiniFutures ] 

#17-679 Listing of instruments issued by BNP Paribas Issuance B.V.

As from July 21, 2017, 2 instruments issued by BNP Paribas Issuance B.V. will be listed on NDX Structured Products Sweden. The instrument will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Agent: Exceed For more details see attached file. For further information concerning this NDX notice please contact: NDX Listing on +46 8 566 390 20 or at ndxlist@ngm.se Nordic Growth Market NGM AB About NDX Nordic derivatives Exchange (NDX) is a market for listing and trading of derivatives and other structured products. The market is operated by Nordic

#17-678 Listing of instrument issued by Commerzbank AG

As from July 21, 2017, 1 instrument issued by Commerzbank AG will be listed on NDX Miscellaneous Investment Products Sweden. The instrument will be registered at Euroclear Sweden AB.Issuer: Commerzbank AG Agent: Exceed For more details see attached file. For further information concerning this NDX notice please contact: NDX Listing on +46 8 566 390 20 or at ndxlist@ngm.se Nordic Growth Market NGM AB About NDX Nordic derivatives Exchange (NDX) is a market for listing and trading of derivatives and other structured products. The market is operated by Nordic Growth Market (

#17-333 Listing of Turbo warrants issued by Commerzbank AG

As from July 21, 2017, 4 Turbo warrants issued by Commerzbank AG will be listed on NDX Finland and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Finland Oy.Issuer: Commerzbank AG Type of security: Call and put Turbo warrants of European type Execution: Automatic cash settlement Term: As from July 21, 2017 to expiry date Market Maker: Commerzbank AG Underlying: DAX 30 Index For more details see attached file. For further information concerning this NDX notice please contact: NDX Listing on +46 8 566 390 20 or at

#17-332 Listing of Knock out warrant issued by Commerzbank AG

As from July 21, 2017, 1 Knock out warrant issued by Commerzbank AG will be listed on NDX Finland and will be included on the list for Knock-Outs. The instrument will be registered at Euroclear Finland Oy.Issuer: Commerzbank AG Type of security: Knock out warrant, open ended Execution: Automatic cash settlement Term: As from July 21, 2017 and forward or until time for knock out event Market Maker: Commerzbank AG Underlying: DAX 30 Index Current values of strike and barrier can be found at: [ NGM Market Data Web - KnockOutWarrants ] 

CHANGES TO THE BOARD OF DIRECTORS AT DIGNITANA

Lund, Sweden - July 20, 2017 - Dignitana AB, a world leader in medical scalp cooling technology and manufacturer of the DigniCap® Scalp Cooling System, announced today that Board Member Magnus Nilsson will resign from his position due to changes in his current professional responsibilities.  As CEO of Xvivo Perfusion AB, Magnus Nilsson will move to the United States to develop Xvivo’s U.S. subsidiary during the coming period. Thereby he will spend most of his time abroad. Magnus Nilsson has served as Board Member at Dignitana AB since May 2014. “I would like to thank Magnus for

Konecranes received order for automated RTG system and STS cranes from new customer in Indonesia

In July 2017 Konecranes won a contract for the delivery of an Automated RTG (ARTG) system to a new customer, PT Prima Multi Terminal, a subsidiary of PT Pelabuhan Indonesia I. The ordered ARTG system includes eight ARTG cranes with associated software, interfaces and services. The new order also comprises three Ship-to-Shore (STS) cranes. The ordered ARTG system and the STS cranes will be delivered to the greenfield container terminal in Kuala Tanjung Port, North Sumatera. The terminal is prioritizing digitization right from the beginning and highlighted the importance of transparency,

Interim report January – June 2017 Sweco AB (publ)

Solid operational performance in a good marketApril – June 2017       · Net sales decreased to SEK 4,262 million (4,370) · EBITA decreased to SEK 312 million (462), margin 7.3 per cent (10.6) · EBIT decreased to SEK 299 million (438), margin 7.0 per cent (10.0) · Profit after tax decreased to SEK 225 million (342), corresponding to SEK 1.88 per share (2.85) January – June 2017 · Net sales increased to SEK 8,670 million (8,387) · EBITA increased to SEK 807 million (690), margin 9.3 per cent (8.2) · EBIT increased to SEK 776 million (643), margin 8.9 per cent (7.7)

Read original

Volvo Cars first half 2017 profit up 21.2 per cent to SEK6.8bn

Volvo Cars, the premium car maker, has reported strong growth in operating profit of SEK6.8bn in the first half of 2017, compared to SEK5.6bn for the same period last year, after taking market share across Europe and experiencing a robust sales increase in China. Revenues rose to SEK99.1bn from SEK84.2bn in the first six months of 2016, while the operating profit margin improved to 6.8 per cent from 6.6 per cent a year earlier, even as the company continues to invest heavily in new cars and technologies. Sales for the first six months of the year increased 8.2 per cent compared to the

Recipharm and LIDDS establish industrial manufacturing capabilities for a novel prostate cancer product

Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca®Depot, at Recipharm in Solna, Sweden. The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid®technology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca® Depot or other pharmaceutical formulations based on the NanoZolid®technology. The manufacturing line has been adapted for GMP production and is

Long time Navetti Client Powers their Business with Global Rollout

We are excited to announce that a worldwide electrical component manufacturer has chosen Navetti as their preferred price optimization and price management provider for their entire group. Previously, without a globally synchronized pricing approach, the client had challenges with margin stacking and cost-plus thinking, resulting in lost profit opportunities. By implementing Europe’s most sophisticated pricing software, Navetti PricePoint™, and reorganizing their product segmentation and business structure, our client will be able to fully utilize their data and resources and eliminate

Exel Composites Plc’s January–June Half-year Financial Report 2017: “Significant increase in order intake, revenue and operating profit”

EXEL COMPOSITES PLC       HALF-YEAR FINANCIAL REPORT       20 JULY 2017 at 10:00 EETQ2 2017 in brief · Order intake increased by 15.5% to EUR 23.4 million (Q2 2016: 20.2). · Revenue increased by 17.4% to EUR 23.2 million (19.7). · Adjusted operating profit improved to EUR 1.7 million (1.2), which is 7.4% of revenue (5.9%). · Net cash flow from operating activities was EUR 1.1 million (0.3). · Earnings per share amounted to EUR 0.09 (0.07). H1 2017 in brief · Order intake increased by 19.8% to EUR 45.8 million (38.3). · Revenue increased by 15.4% to EUR 43.4

Notice to extraordinary general meeting

Shareholders of Caperio Holding AB (publ), 556680-2673 (the "Company"), are hereby invited to attend the extraordinary general meeting at 14.00 CET on 3 August 2017 at the offices of Advokatfirman Vinge, Smålandsgatan 20, Stockholm, Sweden.Participation A shareholder who wish to attend the meeting must · be listed in the shareholders' register maintained by Euroclear Sweden AB on 28 July 2017, and · notify the Company of its intention to attend the meeting no later than on 28 July 2017. Notification shall be made in writing to Caperio Holding AB, P.O. Box 111 05, SE-161 11 Bromma,

Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol Medical AB, regarding the fundamental strategy behind the company’s recent IPO and important lessons learned from that process. The article has been made available and can be read via the link below: http://media.isofol.se/2017/07/ExecutiveInterviewScrip.pdf  Scrip intelligence – Pharmaceutical and biotech intelligence division of Informa Scrip intelligence is a leading source of news and strategic analysis for the global pharmaceutical industry,

Lindab International AB (publ): Lindab's Report for the Second Quarter 2017

Second Quarter 2017 · Net sales increased by 5 percent to SEK 2,118 m (2,016), of which organic growth amounted to 2 percent. · Adjusted[1)] operating profit increased by 9 percent to SEK 151 m (139). Operating profit increased to SEK 151 m (138). · Adjusted[1)] operating margin increased to 7.1 percent (6.9). · Profit for the period increased by 23 percent to SEK 106 m (86). · Earnings per share increased to SEK 1.39 (1.13). · Cash flow from operating activities amounted to SEK 162 m (187). · The net debt/equity ratio amounted to 0.4 (0.5) at the end of

Interim Report January-June 2017: Execution of the strategy and transformation to meet the challenge of digitization is on schedule

APRIL-JUNE 2017 · Net sales SEK 9,083m (9,590).  · Operating income SEK -291m (-270). · Adjusted operating income SEK -4m (-1). · Items affecting comparability, net, SEK -287m (-269). · Net income for the period SEK -336m (-282). · Earnings per share, SEK -0.17 (-0.14). · Cash flow from operating activities SEK 922m (364). JANUARY-JUNE 2017 · Net sales SEK 18,431m (19,228). · Operating income SEK -197m (30).  · Adjusted operating income SEK 188m (299). · Items affecting comparability, net, SEK -386m (-269). · Net income for the period SEK -320m (-

Read original

Episurf Medical has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers

Episurf Medical (NASDAQ: EPIS B) has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers with 39 hospitals, 10 clinics and two specialist cancer care centres across England, Wales and Scotland. The decision has been made following a review process.  “We are very pleased that, with the support from some of the UK’s leading surgeons, Episealer® has received approval from Spire Healthcare as a new treatment method for focal cartilage and bone damages of the knee”, says Pål Ryfors, CEO Episurf Medical. “Spire Healthcare delivers a very high

Combitech’s half-year report for January-June 2017

The technical consultancy company Combitech, an independent subsidiary of the defence and security company Saab AB, is releasing its interim report today for January-June 2017. The report shows continued increases both in sales and earnings.Summary of highlights during the second quarter of 2017:    · The annual digitalisation event Techxperience Day was held on 2 May, and attracted a large number of decision-makers in the industry. This year’s theme was innovation, security and autonomy, and the participants also emphasised the importance of collaboration between different

Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder

–      If approved, CAM2038 would provide weekly and monthly dosing options for patients with Opioid Use Disorder –      Priority Review of the NDA has been applied for which, if granted, would shorten the review process of CAM2038  –      Robust clinical dossier supports potential for novel subcutaneous buprenorphine depotsLund, Sweden and Princeton, N.J. — July 20, 2017 — Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals (“Braeburn”) today announced the completion of the rolling submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top